The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jan 25

PMID 22272343

Citations 74

Authors

Yong Jae Shin

Jeong-Ho Kim

Affiliations

Soon will be listed here.

Abstract

Degradation of the extracellular matrix (ECM), a critical step in cancer metastasis, is determined by the balance between MMPs (matrix metalloproteinases) and their inhibitors TIMPs (tissue inhibitors of metalloproteinases). In cancer cells, this balance is shifted towards MMPs, promoting ECM degradation. Here, we show that EZH2 plays an active role in this process by repressing the expression of TIMP2 and TIMP3 in prostate cancer cells. The TIMP genes are derepressed by knockdown of EZH2 expression in human prostate cancer cells but repressed by overexpression of EZH2 in benign human prostate epithelial cells. EZH2 catalyzes H3K27 trimethylation and subsequent DNA methylation of the TIMP gene promoters. Overexpression of EZH2 confers an invasive phenotype on benign prostate epithelial cells; however, this phenotype is suppressed by cooverexpression of TIMP3. EZH2 knockdown markedly reduces the proteolytic activity of MMP-9, thereby decreasing the invasive activity of prostate cancer cells. These results suggest that the transcriptional repression of the TIMP genes by EZH2 may be a major mechanism to shift the MMPs/TIMPs balance in favor of MMP activity and thus to promote ECM degradation and subsequent invasion of prostate cancer cells.

Citing Articles

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.

Hsu C, Mohammed A, Hjazi A, Uthirapathy S, Renuka J, Singh A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960560 DOI: 10.1007/s00210-025-03883-9.

Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.

Zheng D, Zhang Y, Yang S, Su N, Bakhoum M, Zhang G Cell Death Discov. 2024; 10(1):246.

PMID: 38777812 PMC: 11111810. DOI: 10.1038/s41420-024-02031-1.

Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST.

Li W, Zheng D, Zhang Y, Yang S, Su N, Bakhoum M Res Sq. 2023; .

PMID: 37886478 PMC: 10602109. DOI: 10.21203/rs.3.rs-3270539/v1.

Apelin Promotes Prostate Cancer Metastasis by Downregulating TIMP2 via Increases in miR-106a-5p Expression.

Lin T, Chang S, Khanh P, Trang N, Liu S, Tsai H Cells. 2022; 11(20).

PMID: 36291151 PMC: 9600532. DOI: 10.3390/cells11203285.

PRC2 loss drives MPNST metastasis and matrix remodeling.

Brockman Q, Scherer A, McGivney G, Gutierrez W, Voigt A, Isaacson A JCI Insight. 2022; 7(20).

PMID: 36066973 PMC: 9714789. DOI: 10.1172/jci.insight.157502.

References

Fujii S, Ito K, Ito Y, Ochiai A . Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008; 283(25):17324-32. PMC: 2427338. DOI: 10.1074/jbc.M800224200. View

DeClerck Y, Perez N, Shimada H, Boone T, Langley K, Taylor S . Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992; 52(3):701-8. View

Freije J, Balbin M, Pendas A, Sanchez L, Puente X, Lopez-Otin C . Matrix metalloproteinases and tumor progression. Adv Exp Med Biol. 2003; 532:91-107. DOI: 10.1007/978-1-4615-0081-0_9. View

Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins S . Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007; 12(5):419-31. DOI: 10.1016/j.ccr.2007.10.016. View

Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D . Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002; 16(22):2893-905. PMC: 187479. DOI: 10.1101/gad.1035902. View

Varambally S, Dhanasekaran S, Zhou M, Barrette T, Kumar-Sinha C, Sanda M . The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-9. DOI: 10.1038/nature01075. View

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C . The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005; 439(7078):871-4. DOI: 10.1038/nature04431. View

John A, Tuszynski G . The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001; 7(1):14-23. DOI: 10.1007/BF03032599. View

Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T . Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 2005; 25(1A):183-91. View

10.

Leco K, Khokha R, Pavloff N, Hawkes S, Edwards D . Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994; 269(12):9352-60. View

11.

Kirmizis A, Bartley S, Kuzmichev A, Margueron R, Reinberg D, Green R . Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004; 18(13):1592-605. PMC: 443521. DOI: 10.1101/gad.1200204. View

12.

Jarvelainen H, Sainio A, Koulu M, Wight T, Penttinen R . Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009; 61(2):198-223. PMC: 2830117. DOI: 10.1124/pr.109.001289. View

13.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

14.

Friedl P, Wolf K . Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3(5):362-74. DOI: 10.1038/nrc1075. View

15.

Deryugina E, Quigley J . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25(1):9-34. DOI: 10.1007/s10555-006-7886-9. View

16.

Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P . Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-43. DOI: 10.1126/science.1076997. View

17.

Daja M, Niu X, Zhao Z, Brown J, Russell P . Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2003; 6(1):15-26. DOI: 10.1038/sj.pcan.4500609. View

18.

Karanikolas B, Figueiredo M, Wu L . Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res. 2009; 7(9):1456-65. PMC: 2794652. DOI: 10.1158/1541-7786.MCR-09-0121. View

19.

Kawamata H, Kawai K, Kameyama S, Johnson M, Stetler-Stevenson W, Oyasu R . Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer. 1995; 63(5):680-7. DOI: 10.1002/ijc.2910630513. View

20.

Min J, Zaslavsky A, Fedele G, McLaughlin S, Reczek E, De Raedt T . An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010; 16(3):286-94. PMC: 2903662. DOI: 10.1038/nm.2100. View